SEM-CM14D-100μg / 询价
SEM-CM14D-500μg / 询价
SEM-CM14D-500μgx2 / 询价
- 客服电话
- 技术支持
Cynomolgus Semaphorin 4D/SEMA4D/CD100 Protein
Recombinant Cynomolgus Semaphorin 4D/SEMA4D/CD100 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Phe24-Arg734 [Accession | A0A2K5TZC9].
The protein has a predicted MW of 80.1 kDa. Due to glycosylation, the protein migrates to 90-120 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Cynomolgus Semaphorin 4D on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Cynomolgus Semaphorin 4D is greater than 95% as determined by SEC-HPLC.
Immobilized Cynomolgus Semaphorin 4D, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Anti-Semaphorin 4D Antibody , hFc Tag with the EC50 of 11.8ng/ml determined by ELISA.
Semaphorin 4D (Sema4D) is a multifunctional protein widely expressed in an organism that plays an important role in the control of many physiological and pathological processes, including immunoregulation, neurogenesis, angiogenesis, and tumor progression.
Semaphorin-4D; CD100; SEMA4D; C9orf164; FLJ33485; FLJ34282; FLJ39737; FLJ46484; M-sema-G; MGC169138; MGC169141; SEMAJ; coll-4
(1)Semaphorin 4D (Sema4D) is a multifunctional protein widely expressed in an organism that plays an important role in the control of many physiological and pathological processes, including immunoregulation, neurogenesis, angiogenesis, and tumor progression.
